BIOF: the cash flow

MyFinsight

For the quarter ending 2026-03-31, BIOF had -$56,535 decrease in cash & cash equivalents over the period.

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Accounts payable and accrued liabilities	-	-	-	31,495
Net income (loss)	-663,801	-1,287,469	-422,547	-1,164,585
Depreciation and amortization	31,377	18,412	31,417	96,023
Stock based compensation	76,855	266,222	288,699	465,557
Issuance of warrants for interest expense	4,303	0	6,328	18,149
Prepaid expenses	-	-21,238	0	300
Accounts payable	-62	-16,721	-49,371	-
Accounts payable - related party	-	-24,100	-	-
Deferred wages and directors fees -- related party	155,925	635,175	30,529	251,561
Interest payable - related party	-24,000	0	-9,219	0
Right of use lease	4,199	-	-1,690	-3,377
Net cash provided by (used in) operating activities	-418,535	-392,310	-153,969	-298,723
Purchase of property and equipment	-	-1	-67,252	136,151
Deposit on land	-	-	0	50,000
Payment of deposit on property	10,000	50,000	-	-
Additions to patent and trademark costs	-	10,185	1,115	7,147
Net cash provided by (used in) investing activities	-10,000	-10,184	66,137	-193,298
Proceeds from issuance of common stock and warrants	227,000	310,000	175,000	260,000
Proceeds from the issuance of convertible notes - rp	-	185,000	-	0
Proceeds from the exercise of warrants	125,000	62,500	0	6,250
Proceeds from the issuance of notes payable -- rp	-165,000	-	0	185,000
Net cash provided by financing activities	372,000	372,500	175,000	451,250
Net increase (decrease) in cash and cash equivalents	-56,535	-29,994	87,168	-40,771
Cash and cash equivalent at beginning of the period	65,200	95,194	48,797	-
Cash and cash equivalent at end of the period	8,665	65,200	95,194	-

Unit: Dollar. Numbers labeled with * are estimated quarterly values.